The FDA and Vaccine Policy: A Tutorial on Roles, Responsibilities, and Common Mistakes

Overview

In early 2025, FDA Commissioner Marty Makary resigned after a controversial tenure marked by a public announcement that the COVID-19 vaccine would no longer be routinely recommended for healthy pregnant women and children. This statement, made alongside HHS Secretary Robert F. Kennedy Jr. and NIH Director Jay Bhattacharya, revealed a fundamental misunderstanding of the FDA’s role: the agency approves vaccines for safety and efficacy, but it does not set immunization policy—that is the purview of the CDC’s Advisory Committee on Immunization Practices (ACIP). This tutorial unpacks that misstep and provides a clear framework for understanding how the FDA and CDC interact in vaccine policy. You’ll learn the statutory boundaries, common pitfalls for agency leaders, and how to avoid similar confusion.

Prerequisites

Before diving in, you should be familiar with basic U.S. health agency structures. Ideally, you’ve followed the COVID-19 pandemic response and understand terms like ‘emergency use authorization’, ‘routine recommendation’, and ‘ACIP’. No legal or medical background is required, but a willingness to engage with regulatory nuance helps. This tutorial is designed for public health professionals, journalists, policy advocates, and anyone seeking clarity on how vaccine decisions are made at the federal level.

Step-by-Step Guide to Understanding the FDA’s Role in Vaccine Policy

Step 1: Recognize the FDA’s Statutory Mission

The Food and Drug Administration exists to ensure medical products—including vaccines—are safe, effective, and properly labeled. Its authority stems from the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. When a vaccine receives FDA approval or emergency use authorization, it means the agency has determined that the benefits outweigh the risks for the intended population. However, the FDA does not dictate who should receive a vaccine as a matter of public health policy. That distinction is crucial: approval is a regulatory decision, not a recommendation.

For example, in 2021 the FDA fully approved the Pfizer-BioNTech COVID-19 vaccine for individuals aged 16 and older. But the CDC’s ACIP then deliberated on whether to recommend it for specific age groups or populations. The FDA commissioner has no formal role in that ACIP vote.

Step 2: Distinguish Between FDA Approval and CDC Recommendations

The Centers for Disease Control and Prevention, through its ACIP, develops vaccination schedules for the general U.S. population. While the FDA determines that a vaccine is safe and effective, the CDC decides how to use it in public health practice. This includes defining routine vs. non-routine recommendations for subgroups such as pregnant women, children, or immunocompromised patients. The process involves expert review, public comment, and a formal vote.

Key takeaway: FDA approval is a yes/no on the product; CDC recommendation is a yes/no on the policy. Makary’s announcement conflated the two—he spoke as though the FDA could unilaterally change routine use recommendations, which it cannot.

Step 3: Analyze the Makary Incident as a Case Study

On that Tuesday in early 2024, Makary, Kennedy, and Bhattacharya posted a 58-second video on X (formerly Twitter) stating that the COVID-19 vaccine would no longer be “routinely recommended” for healthy pregnant women and children. This was not preceded by any ACIP review or CDC guideline update. The trio appeared to be acting on their own authority as leaders of HHS, FDA, and NIH. But each agency has a specific lane: NIH conducts research, FDA regulates products, and HHS oversees both. None of these agencies independently sets vaccine policy.

The result? Confusion, criticism from public health experts, and an eventual clarification from the CDC that its recommendations remained unchanged. Within a year, Makary resigned, partly due to this and other controversies. The incident perfectly illustrates how a leader’s misunderstanding of agency boundaries can undermine trust and create policy chaos.

Step 4: Identify the Core Misunderstanding

Makary’s error was not just procedural—it reflected a deeper misreading of the FDA’s role. He seemed to believe the FDA commissioner could issue population-level policy directives without CDC input. In reality, the FDA is a science-based regulatory agency, not a policy arm of the executive branch. Even the HHS Secretary has limited ability to override ACIP recommendations without going through a formal review process. The commissioner’s job is to oversee product approval, not to decide who gets vaccinated.

This confusion is not unique to Makary. Many new political appointees assume their title grants them sweeping authority over public health policy. The lesson: read the laws and understand the interagency decision-making hierarchy before making public pronouncements.

Common Mistakes When Interpreting FDA Authority

• Mistaking approval for recommendation: Just because the FDA approves a vaccine does not mean it is automatically recommended for everyone. The ACIP weighs additional factors like disease burden and equity.
• Overstepping during public health emergencies: In a crisis, officials may feel pressure to act quickly. But skipping established processes (like ACIP review) can backfire, eroding public trust.
• Assuming the FDA commissioner speaks for the entire health agency: The FDA is one piece of a larger puzzle. The NIH, CDC, and HHS all have distinct functions. No single leader can unilaterally change vaccine policy.
• Ignoring the legal framework: The FDA’s authority is set by statute; executive orders or political statements cannot overrule it without legislative change.

Summary

Marty Makary’s resignation highlights a persistent misunderstanding of the FDA’s role in vaccine policy. The FDA approves vaccines for safety and efficacy; the CDC, via ACIP, decides on recommendations for use. Leaders who conflate these functions risk public confusion and policy breakdown. This tutorial has walked you through the key steps to avoid that mistake: recognizing the FDA’s mission, distinguishing it from the CDC’s, analyzing real-world examples, and identifying common pitfalls. For anyone involved in health policy or communication, mastering this distinction is essential to maintaining credibility and effective governance.